MPS I

Mucopolysaccharidoses (MPS) is a rare, autosomal, genetic disorder that occurs in adults and children with a combined incidence of 1:50,000. This disease can be classified in three phenotypes: MPS IH (Hurler Syndrome) MPS HIS (Hurler-Scheie Syndrome) and MPS IS (Scheie Syndrome). All of these types share the absence of a specific enzyme, α-L-iduronidase which when missing, promotes abnormal storage of glycosaminoglycans or GAGs (dermatan and heparan sulfate). Without the enzyme, the breakdown process of GAGs is incomplete. Partially broken down dermatan and heparan sulfate accumulates in the body's cells and tissues causing a loss of function or deterioration in one or several crucial areas of the body. Depending on the diagnosis type, this may result in mental and physical disability as well as drastically shortened lifespan of the affected.

Genzyme Canada is committed to provide opportunities for the development of treatment into this classification of disease with clinical trials and educational symposiums to improve the quality of life for sufferers and their families.

For more information on MPS I and other related Lysosomal Storage Diseases please contact Genzyme Canada at (905) 625-0011 or toll-free at 1-877-220-8918.

Privacy Policy - Canada USA | Terms and Conditions of Use | | © 2003-2012 Genzyme, a Sanofi company. All rights reserved.